Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, et al. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome.
Mov Disord 2007;22:1145-9
Antonini A, Manici F, Canesi M, Zangaglia R, Isaias IU, Manfredi L, et al. Duodenal levodopa infusion improves qualitiy of life in advanced Parkinson’s disease.
Neurodegener Dis 2008;23:244-6
Benabid AL, Pollak P, Louveau A, Henry S, de Rougement J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson’s disease. Appl Neurophysiol 1987;30:344-6
Benabid AL, Benazzouz A, Hoffmann D, Limousin P, Krack P, Pollak P: Long-term electrical inhibition of deep brain stimulation targets in movement disorders. Mov Disord 1998;13 Suppl 3:S119-S125
Berney A, Vingerhoets F, Perrin A, Guex P, Villemure JG, Burkhard PR, et al. Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology 2002;59:1427-9
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-55
Beyer MK, Herlofson K, Arsland D, Larsen JP. Causes of death in a community-based study of Parkinson’s disease. Acta Neurol Scand 2001;103:7-11
Birkmayer W, Hornykiewicz O. Der L-dioxyphenylalanineffekt bei der Parkinson-Akinese. Wien Klin Wschr 1961;73:787-8
Bower JH, Maraganore DM, Mc Donnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52:1214-20
Bredberg E, Nilsson D, Johansson K, Aquilonius SM, Johnels B, Nyström C et al.
Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson’s disease. Eur J Clin Pharmacol 1993;45:117 -22
Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson’s disease pathology spread. Nat Rev Neurosci 2008;9:741-5
Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-Hydroytryptophan as Reserpine Antagonists. Nature 1957;180:1200
Ceballos-Baumann A. Kontinuierliche Therapie mit der Apomorphinpumpe (Conituous Subcutaneous Infusion Therapy with the Apomorphine Pump) Akt Neurol 2011;38 Suppl 1:S17-S26
Cenci MA. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 2007;30:236-43
Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the Motor Complications of Parkinson’s Disease on the Quality of Life. Mov Disord 2005;20:224–30
Chase TN. Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine. Neurology 1998a;50 Suppl 5:S17-S25
Chase TN, Oh JD, Blanchet PJ. Neurostriatal mechanisms in Parkinson’s disease.
Neurology 1998b;51 Suppl 2:S30-S35
Chase TN. The significance of continous dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs 1998c;55 Suppl 1:1-9
Clarke CE, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinsin’s disease. Parkinson Relat Disord 2009;15:728-41
Danmodis, Danish Movement Disorder Society; Swemodis, Swedish Movement Disorder Society. Duodopa: Scandinavian Consensus I. Treatment with Levodopa/carbidopa gel (Duodopa®) in patients with advanced Parkinson’s disease.
Available at:
http://info.parkinsonforbundet.se/wp-content/uploads/duodopakonsensus-20081.pdf (last accessed 18. August 2010)
De Gaspari D, Siri C, Landi A, Cilia R, Bonetti A, Natuzzi F, et al. Clinical and neurophysiological follow up at 12 months in patient with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006;77:450-3
Deane KH, Jones D, Playford ED, Ben-Shlomo Y, Clarke CE. Physiotherapy for patients with Parkinson’s Disease: a comparison of techniques. Cochrane Database Syst Rev. 2001;(3): CD 002
Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Botzel K, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006;355:896-908
Devos D; French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord 2009;24:993-1000
Dewey RB, Hutton T, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected Apomorphine for parkinsonian off-state events. Arch Neurol 2001;58:1385-92
Di Rocco AD, Molinari SP, Kollmeier B, Yahr MD. Parkinson’s disease:
Progression and Mortality in the L-Dopa Era. Adv Neurol 1996;69:3-11
Diener HC, Putzki N, Hrsg. Leitlinien für die Diagnostik und Therapie in der Neurologie. 4. überarb. Aufl. Stuttgart: Georg Thieme Verlag; 2008
Doshi PK, Chhaya N, Bhatt MH. Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson's disease. Mov Disord 2002;17:1084-5
Duus P. Neurologisch-topische Diagnostik. 6. Aufl. Stuttgart: Georg Thieme Verlag;
1995
Ebersbach G, Hilker R. Medikamentenpumpen und tiefe Hirnstimulation in der Parkinsontherapie – Welche Therapie für welchen Patienten? Akt Neurol 2011;38 Suppl 1:S39-S42
Eggert K, Schrader C, Hahn M, Stamelou M, Rüssmann A, Dengler R et al.
Continuous jejunal levodopa infusion in patients with advanced Parkinson disease:
Practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-66
Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991;552:113-8
Engber TM, Marin C, Susel Z, Chase TN. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
Eur J Pharmacol 1993;236:385-93.
Espay AJ, Chatamra K, Fernandez HH, Standaert DG, Hauser RA, Benesh J, et al.
Interim results of motor-symptom endpoints of an ongoing, openlabel study of levodopa-carbidopa intestinal gel in Parkinson’s disease patients with severe motor fluctuations. Poster presented at: 15th International Congress of Parkinson’s Disease and Movement Disorders; June 5-9, 2011; Toronto, Canada
Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson’s diesease: central pathophysiological mechanisms, Part I.
Ann Neurol 1988;24:366-71
Fearnley JM, Lees AJ. Ageing and Parkinson`s disease: substantia nigra regional selectivity. Brain 1991;114:2283-301
Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of asvanced Parkinson’s disease. Curr Med Res Opin 2011a;27:907-19
Fernandez HH, Espay AJ, Standaert DG, Benesh J, Lenz RA, Caras SD, et al.
Interim results of clinician-rated symptom endpoints of a longterm, openlabel study of levodopa-carbidopa intestinal gel in Parkinson’s disease patients with severe motor fluctuations. Poster presented at: 15th International Congress of Parkinson’s Disease and Movement Disorders; June 5-9, 2011b; Toronto, Canada
Folstein MF, Folstein SE, McHugh PR. Mini-Mental State (a practical method for grading the state of patients for the clinician). J Psychiatr Res 1975;12:189-98
Fraix V, Pollak P, Van Blercom N, Xie J, Krack P, Benabid AL. The effect of subthalamic nucleus stimulation on levodopa-induced dyskinesias in patients with Parkinson’s disease. Neurology 1999;52 Suppl 2:A403-A404
Garcia Ruiz PJ, Sesar Ignacio AS, Ares Pensado B, Castro Garcia A, Alonso Frech F, Alvarez Lopez M, et al. Efficacy in long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord 2008;23:1130-6
Gelb DJ, Oliver E, Gilman S. Diagnostic Criteria for Parkinson Disease. Arch Neurol 1999;56:33–9
Gerlach M, Reichmann H, Riederer P. Die Parkinson-Krankheit. 3. überarb. Aufl.
Wien: Springer Verlag; 2003
Goetz CG, Stebbins GT, Shale HM, Lang AE, Chernik DA, Chmura TA et al. Utility of an objective dyskinesia rating scale for Parkinson’s disease: inter- and intrarater reliability assessment. Mov Disord 1994;9:390-4
Goetz CG, Emre M, Dubois B. Parkinson’s disease dementia: definitions, duidelines, and research perspectives in diagnosis. Ann Neurol 2008;64 Suppl 2:S81-S92
Grimbergen YA, Munneke M, Bloem BR. Falls in Parkinson’s disease. Curr Opin Neurol. 2004;17:405-15
Hagell P, Odin P. Apomorphine in the treatment of Parkinson´s disease. J Neurosci Nurs 2001;33:21-34,37-8.
Hagell P, Odin P, Shing M, Hrsg. Apomorphin bei Morbus Parkinson. 1. Aufl.
Bremen: Uni-Med Verlag; 2005
Hawkes CH, Del Tredici K, Braak H. Review: Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007;33:599–614.
Hilker R, Benecke R, Deuschl G, Fogel W, Kupsch A, Schrader C, et al. Tiefe Hirnstimulation bei idiopathischem Parkinson-Syndrom. Nervernarzt 2009;80:646-55
Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-42
Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, et al.
Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74
Honig H, Odin P, Chaudhuri KR. Wirkung von Apomorphin auf nicht motorisch Symptome bei Morbus Parkinson. Akt Neurol 2011;38 Suppl 1:S34-S38
Horowski R, Horowski L, Vogel S, Poewe W, Kielhorn FW. An essay on Wilhelm von Humboldt and the shaking palsy: First comprehensive description of Parkinson’s disease by a patient. Neurology 1995;45:565-8
Houeto JL, Mesnage V, Mallet L, Pillon B, Gargiulo M, Tezenas du Moncel S, et al.
Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002;72:701-7
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4
Isacson D, Bingefors K, Kristiansen IS, Nyholm D. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion.
Acta Neurol Scand 2008;118:379-86
Jafri NS, Mahid SS, Minor KS, Idstein SR, Hornung CA, Galandiuk S. Meta-analysis: antibiotic prophylaxis to prevent peristomal infection following percutaneous endoscopic gastrostomy. Aliment Pharmacol Ther 2007;25:647-56
Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson’s disease: a baseline analysis of the DAT ATOP cohort.
Neurology 1990;40:1529-34
Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s Disease Questionnaire (PDQ-39); development and validation of a Parkinson’s disease summary index score. Age Ageing 1997;26:353-7
Jenner P. Factors influencing the onset and persistence of dyskinesias in MPTP-treated primates. Ann Neurol 2000;47 4 Suppl 1:S90-S99
Johnels B, Ingvarsson PE, Thorselius M, Valls M, Steg G. Disability profiles and objective assessment in Parkinson’s disease. Acta Neurol Scand 1989;79:227-38
Karlsborg M, Korbo L, Regeur L, Glad A. Duodopa pump treatment in patients with advanced Parkinson’s disease. Dan Med Bull 2010;57:A4155
Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, et al.
Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-7
Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, et al.
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006;21 Suppl 14:S290-S304
Krack P, Pollak P, Limousin P, Benazzouz A, Deuschl G, Benabid AL. From off-period dystonia to peak-dose chorea: the clinical spectrum of varying subthalamic nucleus activity. Brain 1999;122:1133-46
Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-34
Kumar R, Lozano AM, Kim YJ, Hutchison WD, Sime E, Halket E, Lang AE.
Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson’s disease. Neurology 1998;51:850-5
Krack P, Kumar R, Ardouin C, Dowsey PL, McVicker JM, Banabid AL, Pollak P.
Mirthful laughter induced by subthalamic nucleus stimulation. Mov Disord 2001;16:867-75
Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A, Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986;20:262–5
Kurth MC, Tetrud JW, Tanner CM, Irwin I, Stebbins GT, Goetz CG, Langston JWl.
Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson’s disease patients with „on-off“-fluctuations.
Neurology 1993;43:1698-703
Lees A, Turner K. Apomorphine for Parkinson´s disease. Practical Neurology 2002;2:280-6
Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet 2009;373:2055-66
Lewy FM. Zur pathologischen Anatomie der Paralysis agitans. Dtsch Z Nervenheilk 1913;50:50-5
Li JY, Englund E, Widner H, Rehncrona S, Björklund A, Lindvall O, Brundin P.
Characterization of Lewy body pathology in 12- and 16-year old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord 2010;25:1091-6
Lindgren HS, Rylander D, Ohlin KE, Lundblad M, Cenci MA. The „motor complication syndrome“ in rats with 6-OHDA lesions treated chronically with l-DOPA: relation to dose and route of administration. Behav Brain Res 2007;177:150-9
Lindgren HS, Ohlin KE, Cenci MA. Differential involvement of D1 and D2 dopamine receptors in l-DOPA-induced angiogenetic activity in a rat model of Parkinson’s disease. Neuropsychopharmacology 2009;34:2477-88
Lipp A, Lusardi G. Systematic antimicrobial prophylaxis for percutanous endoscopic gastrostomy (review). Cochrane Database Syst Rev 2006;CD005571
Lundqvist C, Nystedt T, Reiersten O, Grotli R, Beiske AG. Continuous treatment with levodopa of Parkinson’s disease. Tidsskr Nor Laegeforen 2005;125:2638-40
Mazzella L, Yahr MD, Marinelli L, Huang M, Moshier D, Di Rocco A. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson’s disease on L-dopa monotherapy 2005, Parkinsonism Relat Disord 2005;11:151-5
May PR, Lee MA, Bacon RC. Quantitative assessment of neuroloeptic-induced extrapyramidal symptoms: clinical and nonclinicalapproaches. Clin Neuropharmacol 1983;6:35-51
Melamed E, Olanow CW, Nutt JG, Lang AE. Dyskinesia assessment workshop:
report from the working groups. Mov Disord 1999;14 Suppl 1:S69-S73
Mendis T, Suchowersky O, Lang A, Gauthier S. Management of Parkinson’s disease a review of current and new therapies. Can J Neurol Sci 1999;26:89-103
Meppelink AM, Nyman R, van Laar T, Prins T, Leenders KL. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson’s disease.
Mov Disord 2011;26:331-4
Morgante L, Salemi G, Meneghini F, Di Rosa AE, Epifanio A, Grigoletto F, et al.
Parkinson disease survival: a population-based study. Arch Neurol 2000;57:507-12
Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F, et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson´s disease: a follow-up of two years. Arch Gerontol Geriatr 2004;38 Suppl 1:291-6.
Müller T. Medikamentöse Therapie des Morbus Parkinson. 2. Aufl. Bremen: Uni-med Verlag; 2002
National Institute for Health and Clinical Excellence. Parkinson’s disease: diagnosis
and management in primary and secondary care,
http://www.nice.org.uk/nicemedia/pdf/cg035niceguideline.pdf (accessed 07.08.08)
Nilsson D, Hansson LE, Johansson K, Nyström C, Paalzow L, Aquilonius SM.
Long-term intraduodenal infusion of water based levodopa-carbidopa dispersion in very advanced Parkinson’s disease. Acta Neurol Scand 1998;97:175-83
Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand 2001;104:343-8
Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernas H, Nyström C, Aquilonius SM. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-63
Nyholm D, Aquilonius SM. Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Clin Neuropharmacol 2004;27:245-56
Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005a;64:216-23
Nyholm D, Jansson R, Willows T, Nilsson Remahl I. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 2005b;65:1506-7
Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H. Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluktuations. Acta Neurol Scand 2009;119:345-8
Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson’s disease: implications for the early use of COMT inhibitors. Neurology 2000;55 Suppl 4:S72-S77
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang AE,et al. ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361:1268-78
Ostergaard L, Werdelin L, Odin P, Lindvall O, Dupont E, Christensen PB, et al. Pen injected apomorphine against off phenomena in late Parkinson´s disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;58:681-7.
Oxford Centre for Evidence-based Medicine. Levels of evidence, http://www.cebm.net/levels_of_evidence.asp#levels (accessed 07.08.08)
Pålhagen SE, Dizdar N, Hauge TB, et al. Long-term study on clinical benefits and qualitiy-of-life of intraduodenal levodopa in routine care for a cohort of treatment-naîve patients with advanced Parkinson’s disease. Poster presented at: 62nd Annual Meeting of the American Academy of Neurology; April 10 – 17, 2010; Toronto, Canada
Parkin SG, Gregory RP, Scott R, Bain P, Silburn P, Hall B, et al. Unilateral and bilateral pallidotomy for idiopathic Parkinson’s disease: a case series of 115 patients.
Mov Disord 2002;17:682-92
Parkinson J. An Essay on the Shaking Palsy. J Neuropsychiatry Clin Neurosci 2002;14:223-36
Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson`s disease. J Neuropathol Exp Neurol 1991;50:743-55
Pechevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G , Ziegler M. Trial Study Group. Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005;12:956–63
Pollak P, Benabid AL, Limousin P, Benazzouz A, Le Bas JF, Perret J. Subthalamic nucleus stimulation alleviates akinesia and rigidity in parkinsonian patients. Adv Neurol 1996;69:591-4
Pollak P, Benabid AL, Krack P, Limousin P, Benazzouz A. Deep brain stimulation.
In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. 3rd ed. Baltimore (MD): Williams&Wilkins; 1998. p.1085-101
Puente V, De Fabregues O, Oliveras C, Ribera G, Pont-Sunyer C, Vivanco R, et al.
Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson’s disease: impact on control of fluctuations and quality of life.
Parkinsonism Relat Disord 2010;16:218-21
Quinn N, Critchley P, Marsden CD. Young onset Parkinson’s disease. Mov Disord 1987;2:73-91
Rajput AH, Fenton ME, Birdi S, Macaulay R, George D, Rozdilsky B, et al. Clinical-pathological study of levodopa complications. Mov Disord 2002;17:289-96
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, Abdalla M.
056 Study Group. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 2006;21:1844-50
Reichmann H, et al. Im Fokus: L-Dopa-Pumpe, Apomorphin-Pumpe, Tiefe Hirnstimulation. Thieme Drug Report 2009;4:1-11
Riederer P, Wuketisch S. Time course of nigrostriatal degeneration in Parkinson´disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976;38:277-301
Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, Rehncrona S, et al.
Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up. Brain 2005;128:2240-9
Sage JI, Schuh L, Heikkila RE, Duvoisin RC. Continous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson’s disease. Clin Neuropharmacol 1988a;11:36-44
Sage JI, Trooskin S, Sonsalla PK, Heikkila R, Duvoisin RC. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988b;24:87-9
Sage JL, Trosokin S, Sonsalla PK, Heikkila RE. Experience with continous enteral levodopa infusions in the treatment of 9 patients with advanced Parkinson’s disease.
Neurology 1989;39 Suppl 2:60-3;discussion 72-3
Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson’s disease. Expert Opin Pharmacother 2007;8:657-64
Schrag A, QuinnN. Dyskinesias and motor-fluctuations in Parkinsons’s disease. A community-based study. Brain 2000;123:2297-305
Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 2006;5:355-63
Schüpbach WM, Maltete D, Houeto JL, du Montcel ST, Mallet L, Welter ML, et al.
Neurosurgery at an earlier stage of Parkinson’s disease: a randomized, controlled trial. Neurology 2007;68:267-71
Senard JM. Blood pressure disorders during idiopathic Parkinson’s disease. Presse Med. 2003 Aug 9;32:1231-7
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy-bodies. Nature 1997;388:839-40
Stacy M, Jankovic J. Current approaches in the treatment of Parkinson’s disease.
Annu Rev Med 1993;44:431-40
Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease:
The STRIDE-PD study. Ann Neurol 2010;68:18-27
Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Langström B.
Levodopa-induced changes in synaptic dopamine in patients with Parkinson’s disease as measured by [11 C]raclopiride displacement and PET. Neurology 1996;46:1430-6
Tertiakoff C. Contribution à l’étude de l’anatomie pathologique du locus niger de Soemmering avec quelques déductions relatives à la pathologie des troubles musculaires et de la maladie de Parkinson. Paris: Jouvre; 1919
Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson’s disease: a randomized controlled trial. JAMA 2009;301:63-73
Westin JE, Lindgren HS, Gardi J, Nyengaard JR, Brundin P, Mohapel P, Cenci MA.
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci 2006;26:9448-61
Winkler C, Kirik D, Björklund A, Cenci MA. L-Dopa-induced dyskinesia in the intrastraital 6-hydroxy-dopamine model of Parkinson’s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2002;10:165-86